Research & development spending on drug development in the U.S. 2022

Published by
Matej Mikulic,
Dec 21, 2023
This statistic displays the share of research and development spending on the phases of pharmaceutical drug development in U.S. companies, among PhRMA members, in 2022. The largest share of R&D spending, 48.4 percent, goes towards clinical trials, inclusive of phase I to phase III trials.

Distribution of research and development spending among U.S. companies in 2022

© Statista 2024
Download
Show detailed source information?
Register for free
Already a member?
Log in
Sources

Use Ask Statista Research Service

Release date

December 2023

Region

United States

Survey time period

2022

Special properties

PhRMA members

Supplementary notes

PhRMA = Pharmaceutical Research and Manufacturers of America.
Percentage points exceeding 100 percent are probably due to rounding.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharmaceutical market worldwide "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharmaceutical market worldwide

Overview

5

Segments

7

Companies

8

R&D, patents, new products

8

Outlook

7

Focus: COVID-19 response

6

Further related statistics

9

Further Content: You might find this interesting as well

Statistics

Topics

Global pharmaceutical industryPharmaceutical industry in the U.S.Top pharmaceutical drugsPfizerNovartis
All features, all contents, at all times: Learn more about our professional solutions.

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$959 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.
Menu